Join Drs. Regillo, Goldberg, and Miller to learn about the latest developments in age-related macular degeneration care, the ideal patient for these emerging treatments, and how optometrists and retina specialists can collaborate to help patients optimize outcomes.
This activity is supported by an unrestricted medical education grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 123979, is accredited by COPE for continuing education for optometrists for 1 hour.
Course ID #78496-TD
Activity ID #123979
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Carl D. Regillo, MD, FACS
Chief, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Retina Surgeon
Mid Atlantic Retina
Philadelphia, PA
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist
Bay Area Retina Associates
Walnut Creek, CA
Rebecca Miller, OD
Brooks Eye Associates
Plano, TX
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Carl D. Regillo, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Adverum Biotechnologies, Allergan, Annexon, Apellis, Clearside, EyePoint Pharmaceuticals, Genentech, Graybug, Iveric Bio, Kodiac, NGM, Novartis, and Regenxbio. Grant/Research Support: Adverum Biotechnologies, Allergan, Annexon, Apellis, Genentech, Graybug, Iveric Bio, Kodiac, NGM, Novartis, Opthea, Regeneron, and Regenxbio.
Roger A. Goldberg, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Annexon, Apellis Pharmaceuticals, Genentech, and Regeneron Pharmaceuticals. Grant/Research Support: Aerie Pharmaceuticals, Annexon, Apellis Pharmaceuticals, Carl Zeiss Meditec, Genentech, Novo Nordisk, and Unity Biotechnology. Speaker's Bureau: AbbVie and Genentech.
Rebecca Miller, OD, has no financial relationships with ineligible companies.
The Evolve staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
